Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) EBT (2019 - 2023)

Alx Oncology Holdings' EBT history spans 5 years, with the latest figure at $91.1 million for Q4 2023.

  • For Q4 2023, EBT rose 397.18% year-over-year to $91.1 million; the TTM value through Dec 2023 reached -$24.7 million, up 80.0%, while the annual FY2025 figure was -$497000.0, 99.63% up from the prior year.
  • EBT for Q4 2023 was $91.1 million at Alx Oncology Holdings, up from -$51.0 million in the prior quarter.
  • Across five years, EBT topped out at $91.1 million in Q4 2023 and bottomed at -$51.0 million in Q3 2023.
  • The 5-year median for EBT is -$15.2 million (2021), against an average of -$12.3 million.
  • The largest annual shift saw EBT crashed 234.19% in 2020 before it surged 397.18% in 2023.
  • A 5-year view of EBT shows it stood at -$3.0 million in 2019, then tumbled by 200.89% to -$9.1 million in 2020, then surged by 367.76% to $24.5 million in 2021, then plummeted by 225.28% to -$30.6 million in 2022, then soared by 397.18% to $91.1 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's EBT are $91.1 million (Q4 2023), -$51.0 million (Q3 2023), and -$34.5 million (Q2 2023).